{"filing": {"accession": "0001437749-26-024752", "cik": "0001069530", "ticker": "FLNA", "company_name": "FILANA THERAPEUTICS, INC.", "form_type": "10-Q", "filing_type": "10-Q", "filing_date": "2026-07-29", "accepted_datetime": null, "acceptance_datetime": null, "accepted_at": null, "primary_doc_url": "https://www.sec.gov/Archives/edgar/data/1069530/000143774926024752/0001437749-26-024752-index.htm", "filing_url": "https://www.sec.gov/Archives/edgar/data/1069530/000143774926024752/0001437749-26-024752-index.htm", "period_of_report": "2026-06-30"}, "html_url": "/api/filings/000143774926024752/stream", "exhibits": [{"exhibit_number": "31.1", "exhibit_type": "31", "description": "Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.", "filename": "ex_969148.htm", "edgar_url": "https://www.sec.gov/Archives/edgar/data/1069530/000143774926024752/ex_969148.htm", "category": "other", "incorporated_by_reference": false}, {"exhibit_number": "31.2", "exhibit_type": "31", "description": "Certification of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.", "filename": "ex_969149.htm", "edgar_url": "https://www.sec.gov/Archives/edgar/data/1069530/000143774926024752/ex_969149.htm", "category": "other", "incorporated_by_reference": false}, {"exhibit_number": "32.1", "exhibit_type": "32", "description": "Certification of the Chief Executive Officer and the Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.", "filename": "ex_969150.htm", "edgar_url": "https://www.sec.gov/Archives/edgar/data/1069530/000143774926024752/ex_969150.htm", "category": "other", "incorporated_by_reference": false}, {"exhibit_number": "3.1", "exhibit_type": "3", "description": "Amended and Restated Certificate of Incorporation.", "filename": "", "edgar_url": "https://www.sec.gov/Archives/edgar/data/1069530/000119312505152582/dex31.htm", "category": "incorporation", "incorporated_by_reference": true}, {"exhibit_number": "3.2", "exhibit_type": "3", "description": "Certificate of Amendment of Restated Certificate of Incorporation.", "filename": "", "edgar_url": "https://www.sec.gov/Archives/edgar/data/1069530/000106953017000028/ptie-20170508xex3_1.htm", "category": "incorporation", "incorporated_by_reference": true}, {"exhibit_number": "3.3", "exhibit_type": "3", "description": "Certificate of Amendment of Restated Certificate of Incorporation.", "filename": "", "edgar_url": "https://www.sec.gov/Archives/edgar/data/1069530/000106953019000019/sava-20181231xex3_3.htm", "category": "incorporation", "incorporated_by_reference": true}, {"exhibit_number": "3.4", "exhibit_type": "3", "description": "Certificate of Amendment of Restated Certificate of Incorporation.", "filename": "", "edgar_url": "https://www.sec.gov/Archives/edgar/data/1069530/000143774926007422/ex_929959.htm", "category": "incorporation", "incorporated_by_reference": true}, {"exhibit_number": "3.5", "exhibit_type": "3", "description": "Amended and Restated Bylaws of Filana Therapeutics, Inc.", "filename": "", "edgar_url": "https://www.sec.gov/Archives/edgar/data/1069530/000143774926007422/ex_929960.htm", "category": "incorporation", "incorporated_by_reference": true}, {"exhibit_number": "10.1", "exhibit_type": "10", "description": "Filana Therapeutics, Inc. 2018 Omnibus Incentive Plan", "filename": "", "edgar_url": "https://www.sec.gov/Archives/edgar/data/1069530/000143774926020562/ex_975585.htm", "category": "contracts", "incorporated_by_reference": true}], "sections": [{"section_name": "part_1_item_1", "section_title": "Financial Statements", "start_position": 4403, "end_position": 61558}, {"section_name": "part_1_item_2", "section_title": "Management\u2019s Discussion and Analysis of Financial Condition and Results of Operations", "start_position": 61558, "end_position": 111003}, {"section_name": "part_1_item_3", "section_title": "Quantitative and Qualitative Disclosures About Market Risk", "start_position": 111003, "end_position": 111214}, {"section_name": "part_1_item_4", "section_title": "Controls and Procedures", "start_position": 111214, "end_position": 113144}, {"section_name": "part_2_item_1", "section_title": "Legal Proceedings", "start_position": 113144, "end_position": 114235}, {"section_name": "part_2_item_1a", "section_title": "Risk Factors", "start_position": 114235, "end_position": 114851}, {"section_name": "part_2_item_2", "section_title": "Unregistered Sales of Equity Securities and Use of Proceeds", "start_position": 114851, "end_position": 114927}, {"section_name": "part_2_item_3", "section_title": "Defaults Upon Senior Securities", "start_position": 114927, "end_position": 114975}, {"section_name": "part_2_item_4", "section_title": "Mine Safety Disclosures", "start_position": 114975, "end_position": 115026}, {"section_name": "part_2_item_5", "section_title": "Other Information", "start_position": 115026, "end_position": 115398}, {"section_name": "part_2_item_6", "section_title": "Exhibits", "start_position": 115398, "end_position": 118617}], "tables": [{"table_index": 0, "table_type": "text", "caption": null, "header_text": "(Mark One)"}, {"table_index": 1, "table_type": "text", "caption": null, "header_text": ""}, {"table_index": 2, "table_type": "text", "caption": null, "header_text": "Delaware91-1911336"}, {"table_index": 3, "table_type": "text", "caption": null, "header_text": "Title of each classTradingSymbol(s)Name of each exchange on which registered"}, {"table_index": 4, "table_type": "text", "caption": null, "header_text": "Large Accelerated Filer \u2610Accelerated Filer \u2610"}, {"table_index": 5, "table_type": "text", "caption": null, "header_text": "Common Stock, $0.001 par value48,307,896"}, {"table_index": 6, "table_type": "financial", "caption": null, "header_text": "Page No."}, {"table_index": 7, "table_type": "financial", "caption": null, "header_text": "June 30, 2026December 31, 2025"}, {"table_index": 8, "table_type": "financial", "caption": null, "header_text": "Three months endedSix months ended"}, {"table_index": 9, "table_type": "text", "caption": null, "header_text": "Total"}, {"table_index": 10, "table_type": "financial", "caption": null, "header_text": "Six months ended June 30,"}, {"table_index": 14, "table_type": "financial", "caption": null, "header_text": "Three months endedSix months ended"}, {"table_index": 15, "table_type": "text", "caption": null, "header_text": "June 30, 2026December 31, 2025"}, {"table_index": 16, "table_type": "text", "caption": null, "header_text": "Three months endedSix months ended"}, {"table_index": 17, "table_type": "financial", "caption": null, "header_text": "June 30,December 31,"}, {"table_index": 18, "table_type": "financial", "caption": null, "header_text": "Three months endedSix months ended"}, {"table_index": 19, "table_type": "financial", "caption": null, "header_text": "For the year ending December 31,"}, {"table_index": 20, "table_type": "text", "caption": null, "header_text": "June 30,December 31,"}, {"table_index": 21, "table_type": "text", "caption": null, "header_text": "Stock OptionsPerformance Awards"}, {"table_index": 22, "table_type": "financial", "caption": null, "header_text": "Three months endedSix months ended"}, {"table_index": 23, "table_type": "financial", "caption": null, "header_text": "\u25cfthe timing and conduct of our planned and future potential clinical trials and studies for Simufilam in Tuberous Sclerosis Complex (TSC) and additional indications, including the timing of initiation"}, {"table_index": 24, "table_type": "financial", "caption": null, "header_text": "\u25cfour ability to minimize the likelihood and impact of adverse cybersecurity incidents in our information systems and infrastructure;"}, {"table_index": 25, "table_type": "text", "caption": null, "header_text": "\u25cfa 12-month, open-label treatment phase, followed by"}, {"table_index": 26, "table_type": "text", "caption": null, "header_text": "\u25cfengage with, and satisfactorily respond to, requests for additional information from the FDA concerning the clinical hold on our IND application for simufilam in TSC-related epilepsy"}, {"table_index": 27, "table_type": "text", "caption": null, "header_text": "Three months endedSix months ended"}, {"table_index": 28, "table_type": "financial", "caption": null, "header_text": "\u25cfclinical trials,"}, {"table_index": 29, "table_type": "text", "caption": null, "header_text": "Six months ended June 30,"}, {"table_index": 30, "table_type": "exhibit_index", "caption": null, "header_text": "Incorporated by"}, {"table_index": 31, "table_type": "text", "caption": null, "header_text": "Filana Therapeutics, Inc."}, {"table_index": 32, "table_type": "text", "caption": null, "header_text": ""}], "exhibits_pending": false, "cdn_html": true, "response_time_ms": 37}